The strategy rests on the principles of host-directed therapy, an emerging approach that treats infections by targeting the host’s own biological pathways rather than the pathogen itself. Because host proteins do not mutate at the pace of viral genomes, drugs aimed at host factors are theoretically far less susceptible to the resistance problems that erode the usefulness of direct-acting antivirals. The Korea University team, led by Professor Kwang Yeon Hwang of the College of Life Sciences and Biotechnology and Associate Professor Hong-Rae Kim of the College of Medicine, focused on deoxyhypusine synthase, or DHPS, a human enzyme central to a peculiar biochemical modification known as hypusination.

Hypusination is the process by which eukaryotic translation initiation factor 5A, or eIF5A, is activated through a unique post-translational modification. Once activated, eIF5A supports the replication of a wide spectrum of viruses, which makes DHPS an attractive point of intervention. As Professor Hwang explained, DHPS activates eIF5A through hypusination, a process important for the replication of a broad range of viruses including HIV-1 and SARS-CoV-2, making the enzyme a potential target for host-directed antiviral drug discovery. Inhibiting DHPS would, in principle, starve multiple viruses of a host function they depend upon, without the pathogen being able to escape through simple mutation of its own proteins.

What distinguishes this study from many recent AI drug-discovery efforts is its systematic benchmarking and its insistence on laboratory validation. Rather than showcasing a single algorithm and reporting only computational scores, the researchers evaluated 13 machine-learning models for predicting molecular binding scores and 10 methods for generating entirely new molecules, all against DHPS as a common target. Among the prediction models, an approach called Out-of-Fold Stacking, or OOF-Stacking, achieved the strongest overall performance. Among the generative methods, a technique named RL-Design achieved the highest predicted hit rate, at 92.02 percent, and 98.0 percent of its top-ranked molecules passed a standard drug-likeness threshold, a filter that assesses whether compounds possess physicochemical properties compatible with oral drug development.

The critical test came when the team moved from silicon to the bench. Six fragments, defined as small compounds in the 140 to 190 dalton range, were selected for experimental assessment: three predicted to be active and three predicted to be inactive. The result was a complete agreement between computation and experiment. All three predicted-active fragments inhibited DHPS, and none of the predicted-inactive fragments showed inhibition. Two of the active fragments yielded measurable IC50 values of 31.2 and 49.1 micromolar, concentrations within the range at which fragment hits typically begin to show activity. In fragment-based drug discovery, where starting molecules are deliberately tiny and weakly potent, such values represent a credible starting point rather than a disappointment.

Structural biology provided further confirmation. The researchers obtained an X-ray co-crystal structure showing one of the AI-generated compounds bound at the entrance of the DHPS substrate and NAD-binding pocket, giving direct physical evidence that the computational design had produced a molecule capable of occupying the enzyme’s functional site. This combination of predicted binding, biochemical inhibition, and crystallographic verification forms a chain of evidence that is rarely assembled so completely in early-stage AI drug-discovery studies, which more often stop at docking scores and molecular dynamics simulations without ever synthesizing the proposed compounds.

Professor Kim emphasized that the new fragments differ meaningfully from the best-known DHPS inhibitor, which closely mimics a natural cellular molecule and therefore carries a risk of off-target activity. The AI-generated hits, by contrast, are fragments built on scaffolds unrelated to the known inhibitor. In fragment-based discovery, Kim noted, this is exactly where one wants to start: the molecules are small and bind efficiently for their size, which leaves considerable room to grow them into more potent compounds. He was careful, however, to frame the results appropriately, stressing that these molecules are early-stage hits rather than drug candidates and that further studies will be needed to establish their inhibition mechanisms, selectivity, cellular activity, toxicity, and performance in animal models.

The implications extend well beyond DHPS itself. The pipeline developed by the Korea University team is freely available, meaning that other laboratories could apply the same benchmarked workflow of model comparison, molecular generation, and experimental validation to entirely different disease targets. Equally notable are the pipeline’s modest computing requirements. Many AI-driven discovery efforts depend on enormous computational infrastructure that places them out of reach for smaller academic groups, particularly in resource-limited settings. By demonstrating that meaningful, experimentally validated results can be achieved without such resources, the study suggests a path toward making experimentally grounded, AI-assisted drug discovery far more accessible across the global research community.

The work also arrives at a moment when the lessons of recent pandemics have sharpened interest in antiviral strategies that are harder for pathogens to evade. Host-directed approaches targeting factors such as DHPS could, in principle, yield broad-spectrum antivirals effective against multiple viruses at once, a valuable property when facing emerging pathogens whose identities cannot be predicted in advance. Because the host target remains constant, a single inhibitor might serve as a starting point for therapies against unrelated viral families, something direct-acting antivirals rarely achieve.

For now, the Korea University study stands as a methodological milestone rather than a therapeutic one. It shows that computational predictions can be systematically benchmarked, that generative models can produce chemically plausible and drug-like molecules, and that those molecules can be synthesized and validated in the laboratory with results that match the predictions exactly. The road from a micromolar fragment hit to a selective, non-toxic, clinically useful drug is long and uncertain, and the authors themselves are explicit about the work that remains. Yet the study demonstrates a reproducible route from AI-based molecular design to experimental validation, and in doing so it offers a template that other laboratories, targeting other host factors and other diseases, can now follow.

Subject of Research: AI-guided design and experimental validation of inhibitors targeting the human enzyme DHPS for host-directed antiviral drug discovery

Article Title: Korea University study uses artificial intelligence to design potential antiviral compounds

Article References: Korea University study uses artificial intelligence to design potential antiviral compounds. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: artificial intelligence, drug discovery, host-directed therapy, DHPS, hypusination, antiviral compounds, fragment-based design, machine learning, Korea University, eIF5A, SARS-CoV-2, HIV-1

The scientific program was deliberately broad, spanning nearly every subspecialty within modern urology alongside a dedicated focus on medical education. Sessions addressed artificial intelligence-based prostate cancer diagnosis, a field in which machine learning algorithms are increasingly used to interpret biopsy slides, multiparametric MRI, and clinical risk data to improve detection and risk stratification. Presenters also examined single-port and multi-port robotic surgery, comparing the surgical ergonomics, instrument flexibility, and patient outcomes associated with newer single-incision robotic platforms against the established multi-port systems that have become standard for radical prostatectomy, partial nephrectomy, and other complex urologic procedures.

Bladder cancer management received its own session, framed around treatment strategies in the era of immuno-oncology, with specific attention to the combination of enfortumab vedotin, an antibody-drug conjugate targeting Nectin-4, and pembrolizumab, a PD-1 immune checkpoint inhibitor. This regimen has reshaped the therapeutic landscape for muscle-invasive and metastatic urothelial carcinoma, and the discussion explored how perioperative sequencing of systemic therapy is changing surgical decision-making. Additional sessions covered male health and functional hypogonadism, a condition in which testosterone deficiency produces clinically significant symptoms and metabolic consequences, as well as functional and reconstructive urology with an emphasis on urinary incontinence following prostatectomy, one of the most consequential quality-of-life complications after prostate cancer surgery.

The program also turned to benign prostatic hyperplasia and minimally invasive surgical therapies, a rapidly evolving area in which techniques such as prostatic urethral lift, water vapor thermal therapy, aquablation, and laser enucleation now offer patients alternatives to traditional transurethral resection with reduced sexual and urinary side effects. A further session reviewed the latest surgical treatments for kidney and urinary stones, including advances in ureteroscopy, miniaturized percutaneous nephrolithotomy, and flexible scopes with improved irrigation and visualization. Rounding out the clinical content, the symposium included a comparative analysis of resident training systems in Korea and the United States, examining how differences in duty hours, case volumes, mentorship structures, and certification pathways shape the competence of graduating urologists in each country.

Each session concluded with panel discussions that looked ahead to the future of urology and identified concrete opportunities to expand global collaborative research. These exchanges gave faculty from both institutions a structured forum to propose joint clinical studies, shared registries, and comparative outcomes research that neither institution could easily conduct alone. Participants emphasized that differences in patient populations, screening practices, and health system organization between Korea and the United States make bilateral studies particularly valuable, since findings validated across two distinct settings carry greater generalizability and scientific weight.

A highlight of the meeting came from Dr. Isaac Yi Kim, Chair of the Department of Urology at Yale School of Medicine, who delivered a presentation on the evolution of the United States healthcare system. Dr. Kim analyzed the structural challenges confronting American healthcare, including fragmentation of coverage, cost escalation, and disparities in access, and then broadened the lens through comparisons with the universal health insurance systems of Germany, Japan, and Switzerland. By mapping how those countries organize financing, reimbursement, and delivery of care, he outlined potential directions for future healthcare reform in the United States, offering the audience a policy perspective that is rarely integrated into subspecialty surgical meetings.

The symposium was accompanied by a formal institutional commitment. Korea University’s Anam Hospital and Yale New Haven Hospital signed a memorandum of understanding designed to strengthen cooperation and to widen the scope of academic exchange from urology into broader medical and biomedical fields. Under the agreement, the two hospitals plan to build a comprehensive framework for collaboration across education, research, and clinical practice. Concrete mechanisms include faculty exchange, clinical observation programs, and professional training placements, together with joint training programs and seminars, the sharing of clinical and academic information, and the conduct of joint research projects.

Leaders at both institutions framed the event as the culmination of years of relationship-building rather than a fresh start. Dr. Kang Seok-ho, Chief of the Department of Urology at Anam Hospital, described the symposium as the first collaborative urology meeting of its kind, grounded in the cooperation and trust accumulated over many years between Korea University and Yale. He expressed the hope that the event would become not merely an academic exchange but an opportunity for the two institutions to deepen their collaboration, signaling an intent to translate conference dialogue into sustained joint programs and shared scholarship.

Dr. Pyun Sung-bom, Dean of Korea University College of Medicine, placed the symposium within the wider arc of the institution’s international strategy. He noted that the College of Medicine has maintained active faculty and student exchanges with Yale School of Medicine across a range of disciplines, including medical informatics, neuroscience, oncology, hematology, obstetrics and gynecology, hepato-biliary-pancreatic surgery, cardiology, and urology. Looking forward, he called for expanding cooperation through regular academic exchanges, citing the Infectious Diseases and Immunology Forum and the Urology Symposium as recurring platforms, and argued that these activities will serve as a solid foundation for fostering the next generation of researchers and physician-scientists who will lead the future of medical science.

For the field of urology, the meeting illustrates how academic medical centers are responding to shared clinical challenges with cross-border partnerships. Prostate cancer diagnosis, bladder cancer immunotherapy, robotic surgical technique, stone management, and surgical education are all advancing quickly, yet the pace of progress differs across health systems and patient populations. By institutionalizing exchange through a signed agreement, recurring symposia, and structured training programs, Korea University and Yale are betting that sustained collaboration, rather than isolated conferences, is what converts scientific insight into better patient outcomes on both sides of the Pacific.

Subject of Research: International academic collaboration in urology between Korea University and Yale School of Medicine

Article Title: Korea University College of Medicine hosted Yale-Korea University Urology Symposium

Article References: Korea University College of Medicine hosted Yale-Korea University Urology Symposium. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: urology, Yale School of Medicine, Korea University, robotic surgery, prostate cancer, bladder cancer, immuno-oncology, medical education, healthcare policy, memorandum of understanding, minimally invasive surgery, international collaboration

The research team built their study around a deceptively simple question. Decades of correlational work have linked narrative identity—the internalized, evolving story each person constructs about their own life—to psychological well-being. People whose life stories feature redemption sequences, coherent self-understanding, and growth-oriented interpretations tend to report higher well-being. But correlation is not causation, and experimental evidence has remained thin. A handful of earlier studies, including work by Dorthe Kirkegaard Thomsen and colleagues showing that writing about life story chapters boosts state self-esteem, hinted that the effect was real. What nobody had systematically tested was whether the content of the narrative matters, or whether any structured writing task would do the trick.

Kim and Park designed two experiments to isolate that question. In the first study, 134 Korean adults were randomly assigned to write either a narrative about how they had become the person they are today—a classic life story prompt drawn from Dan McAdams’s life story interview tradition—or a control piece describing what they had done the previous day. Participants rated their self-esteem on the Rosenberg scale and their positive affect on the PANAS immediately before and after writing. The design was deliberately minimal: one writing session, no repeated practice, no therapeutic framing. If a single narrative could shift self-esteem and mood, the effect would have to come from the writing itself rather than from accumulated practice or expectancy.

The results of Study 1 showed that self-esteem and positive affect increased in both conditions, which the authors interpret as a general benefit of structured self-reflection and self-disclosure. But the improvements were not uniform. Participants whose narratives scored higher on three rated features—positivity as judged by the writers themselves, a happy ending as judged by trained coders, and identity formation as judged by coders—showed larger gains in both self-esteem and positive affect. In other words, the story’s emotional arc and its contribution to a sense of self appeared to modulate how much benefit the writer extracted from the exercise.

Study 2 sharpened the picture. With 169 new participants, the team repeated the procedure and added measures of self-motives—the psychological drives, identified in work by Constantine Sedikides and Michael Strube, that push people to enhance, protect, and verify their sense of self. This time the pattern was cleaner and more striking. Self-esteem increased only in the narrative condition; the control group writing about yesterday showed no such lift. Positive affect rose in both groups, but rose significantly more among those who wrote their life story. Once again, narrative positivity, happy endings, and identity formation correlated positively with the size of the improvements, replicating the first study’s findings in an independent sample.

The mediation analysis supplied the theoretical punchline. Self-enhancement—the motive to see oneself in a favorable light—statistically mediated the effect of writing condition on both self-esteem and positive affect. Writing a life story, it seems, hands people a structured opportunity to construct a favorable self-portrait, and that act of favorable self-construction is what translates into the immediate emotional payoff. This finding connects the narrative identity literature to the self-motives literature in a way that prior correlational studies could not. It suggests that the benefit of narrative writing is not merely catharsis or disclosure, mechanisms emphasized in James Pennebaker’s expressive writing tradition, but an active motivational process in which the writer arranges biographical material into a self-flattering, coherent form.

The technical details of the measurement deserve attention because they strengthen the causal claim. The researchers used residualized change scores rather than simple difference scores, a methodological choice recommended in longitudinal analysis because it accounts for regression to the mean and baseline differences between participants. Coders rated the narratives for happy endings and identity formation using established coding schemes, while participants provided their own positivity ratings, capturing both external and internal perspectives on the stories. The mediation model followed modern regression-based approaches, and the data were made openly available on the Open Science Framework, allowing independent verification of the analyses.

Why does the distinction between narrative and control conditions matter so much? The control task—describing the previous day—involved autobiographical writing too, yet it produced weaker or absent effects on self-esteem. The difference lies in what psychologists call autobiographical reasoning. Describing yesterday is a report; narrating how you became who you are is an interpretation, an act of meaning-making that links events to the self. Earlier work by Jack Bauer and Dan McAdams on growth memories, and by Jennifer Lilgendahl and McAdams on autobiographical reasoning in midlife, showed that people who interpret their past through the lens of growth report higher well-being. Kim and Park’s experiments convert that correlational insight into a causal demonstration: prompting the interpretive act produces the benefit, at least in the short term.

The cultural context of the sample adds an important dimension. The studies were conducted with Korean adults, and prior comparative work by the same research group has documented cultural differences in self-construal and coping between East Asian and Western populations. That the narrative writing effect emerged in a cultural setting where self-enhancement is often expressed more modestly than in Western samples suggests the mechanism is robust, though the authors and outside observers alike will want replications across cultures before generalizing. The immediate time frame of the effects is also a boundary condition worth noting. The studies measured self-esteem and positive affect right after a single writing session; whether the boost persists over days or weeks, and whether repeated sessions compound the benefit, remains an open question for future research.

The practical implications are nonetheless tantalizing. Life review and reminiscence interventions have a long clinical history, with meta-analytic evidence showing benefits for late-life depression, and structured writing exercises such as the best possible self task have been used to raise optimism. The new findings offer a refinement: interventions may work better when they explicitly invite positive interpretation and identity formation rather than mere recollection. For anyone tempted to try this at home, the recipe suggested by the evidence is straightforward—write about the experiences that shaped you, and steer the story toward a resolution you can genuinely own. The study’s authors caution that the effects are immediate and modest in scope, not a substitute for therapy, but they illuminate something profound about human psychology: the self is not just remembered, it is authored, and the act of authorship, done well, feels good. The findings, published as Kim and Park in Current Psychology, mark a step toward understanding not only whether life stories matter, but precisely which features of a story carry its psychological weight.

Subject of Research: Experimental effects of single-session narrative writing on self-esteem and positive affect

Article Title: Do narrative features matter for changes in self-esteem and positive affect? evidence from an experimental single-narrative writing design

Article References: Kim, S., & Park, S. W. (2026). Do narrative features matter for changes in self-esteem and positive affect? evidence from an experimental single-narrative writing design. Current Psychology, 45(18), Article 1536. https://doi.org/10.1007/s12144-026-10098-5

Image Credits: AI Generated

DOI: 10.1007/s12144-026-10098-5

Keywords: narrative identity, self-esteem, positive affect, life story writing, self-enhancement, identity formation, happy ending, autobiographical reasoning, well-being, experimental psychology, Current Psychology, Korea University

A new study from Korea University College of Medicine, published in Nature Immunology on June 15, 2026, offers a detailed molecular portrait of how an mRNA-based influenza vaccine may accomplish exactly that. Led by Associate Professor Jiwon Lee of the Department of Convergence Medicine and the Vaccine Innovation Center, and conducted in collaboration with Professor Ali Ellebedy and his group at Washington University in St. Louis, the investigation compared an investigational quadrivalent mRNA influenza vaccine, designated mRNA-1010, against the licensed conventional split-virion vaccine Fluarix in a head-to-head clinical evaluation. The central question was whether the mRNA platform could stimulate stronger and more persistent germinal-center responses than a conventional vaccine, and whether that persistence would translate into a measurably broader antibody repertoire in the blood.

The germinal center is the crucible where vaccine-induced immunity is forged. Within specialized microenvironments of draining lymph nodes, B cells that recognize vaccine antigen undergo rounds of proliferation, somatic hypermutation, and selection. Each cycle introduces random mutations into the genes encoding the B-cell receptor, and only those variants whose mutated receptors bind antigen with higher affinity are permitted to survive and expand. Over weeks, this Darwinian process generates plasma cells that secrete high-affinity antibodies and memory B cells that persist for years. The duration and intensity of germinal-center activity are therefore widely regarded as key determinants of both the breadth and the durability of antibody responses. A vaccine that keeps germinal centers active for longer gives B cells more opportunities to mutate, diversify, and explore antibody solutions that recognize conserved or varied features of the virus.

To test whether mRNA vaccination extends this critical phase, the researchers enrolled 75 healthy adults aged 20 to 50 years and followed them across two influenza seasons. Of these, 38 participants received mRNA-1010 and 37 received Fluarix. Blood samples were collected at multiple time points through 26 weeks after vaccination, allowing the team to track the evolution of circulating antibodies over nearly half a year. Crucially, a subset of participants also underwent ultrasound-guided fine-needle aspiration of draining axillary lymph nodes, an invasive but informative procedure that enabled direct sampling of germinal centers as they formed and matured. This combination of peripheral blood monitoring and lymph-node sampling is rare in human vaccine studies and gave the investigators an unusually complete view of the immune response as it unfolded in real time.

The laboratory analysis was correspondingly comprehensive. The team deployed flow cytometry to characterize immune cell populations, ELISpot assays to quantify antigen-specific antibody-secreting cells, single-cell RNA sequencing and B-cell receptor sequencing to resolve individual B-cell lineages, serum IgG proteomics to catalog circulating antibody clonotypes, and a battery of antibody binding and neutralization assays to test functional activity against antigenically diverse influenza strains. Together, these methods profiled the response at scales ranging from single cells to whole serum, providing a multidimensional dataset that conventional vaccine trials, which typically rely on bulk antibody titers alone, cannot match.

The findings were striking. The mRNA vaccine elicited a substantially more diverse and broader serum antibody repertoire than Fluarix, according to Dr. Lee. Most notably, influenza-specific germinal-center responses persisted for up to 26 weeks in 5 of 13 mRNA-1010 recipients whose draining lymph nodes were sampled, while persistent germinal centers were not detected among any of the Fluarix recipients sampled. Six months of sustained germinal-center activity after a single vaccination is an unusually long window of B-cell evolution, and it suggests that the mRNA platform provides antigen persistence and inflammatory signaling that keep the selection machinery running far longer than a conventional protein-based split-virion preparation.

That prolonged activity left a measurable imprint on the antibody repertoire. The mRNA vaccine increased the diversity of the serum IgG repertoire and promoted the diversification of pre-existing B-cell lineages through somatic hypermutation, meaning that antibodies the immune system had already learned to make against earlier influenza exposures were not merely recalled but actively refined and expanded. These molecular changes were associated with broader antibody binding across antigenically diverse influenza strains and with significantly greater increases in neutralization titers against 11 of 13 A/H1N1 viruses tested. In practical terms, the antibodies generated after mRNA vaccination recognized a wider range of viral variants and neutralized more of them, including strains that differed antigenically from those contained in the vaccine itself. Dr. Lee summarized the distinction succinctly: the mRNA platform does not simply produce more antibodies, it produces a more diversified antibody response, which leads to greater binding and neutralizing breadth.

A key methodological strength of the study was Ig-Seq, a mass-spectrometry-based technology that identifies individual antibody clonotypes circulating in the blood after vaccination. Conventional vaccine studies typically measure bulk binding or neutralization titers, aggregate numbers that reveal how much antibody activity is present but say little about its composition. Ig-Seq resolves the response down to individual antibody clonotypes, revealing which antibody lineages emerged, expanded, and diversified after vaccination. Combined with B-cell receptor sequencing, this molecular-level approach allowed the researchers to trace the genealogical trees of antibody families as they mutated and branched over the six-month observation period, directly linking sustained germinal-center activity in the lymph node to the diversification of antibodies measurable in the serum. The authors identify Ig-Seq as a defining strength of the work because it captures information that bulk serology fundamentally cannot.

The broader implications reach toward the long-sought goal of a more universal influenza vaccine. If mRNA vaccination can sustain germinal-center activity for months rather than weeks, it creates a temporal window in which B cells can accumulate mutations that broaden their recognition of the virus’s antigenic landscape. This mechanism could in principle support protection that carries over between seasons, reducing the need for annual reformulation and re-vaccination. However, the authors are careful to note that further studies are needed to determine whether these broadened responses translate into multi-season protection or permit longer vaccination intervals. The study population consisted of healthy adults aged 20 to 50, and future research must investigate whether the same benefits are maintained in older adults and immunocompromised populations, whose germinal-center function, B-cell repertoire diversity, and overall immune responsiveness differ substantially from those of healthy younger recipients.

What the study establishes, with unusual molecular resolution, is a mechanistic bridge between a vaccine platform and the quality of the immunity it generates. Persistent germinal centers, diversified B-cell lineages, and a broader serum antibody repertoire form a coherent causal chain, and tools such as Ig-Seq now make each link observable in humans. As mRNA technology matures beyond its first applications, findings like these suggest that its most consequential contribution to vaccinology may lie not in speed of development but in the depth and breadth of the immune memory it leaves behind, offering a rational template for influenza vaccines designed to stay ahead of a virus that never stops changing.

Subject of Research: A clinical study comparing mRNA-1010 and Fluarix influenza vaccines in healthy adults, examining germinal-center persistence and antibody repertoire breadth

Article Title: Korea University study uncovers how mRNA vaccination may broaden flu antibody responses

Article References: Korea University study uncovers how mRNA vaccination may broaden flu antibody responses. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: mRNA vaccine, influenza, germinal center, antibody breadth, B cells, somatic hypermutation, Ig-Seq, neutralization, vaccinology, Nature Immunology, Korea University, immune repertoire